In an item carried Dec. 13 called “
Eleven Top Stem Cell Researchers Back Klein for Re-Election,” we wrote,
“All but one of them have tens of millions of dollars at stake in grants from the stem cell agency and are heavily invested in basic research, as opposed to translational efforts to push research into the clinic.”
One of those mentioned by name was
Larry Goldstein of
UC San Diego, who has $14 million in grants from CIRM. Goldstein emailed us today, pointing out that his $11 million grant is not basic research. He said,
“For what it's worth, this grant, which constitutes the bulk of my CIRM funding is not basic research, it is translational with the goal of launching a clinical trial. Many of the statements about my research funding being only basic are incorrect as a result.”
Goldstein from UCSD should be calling the funding from CIRM "our" grant, not "my" grant. The difference is important- The grant is an ALS disease TEAM award written by Salk researchers, with Sam Pfaff, a recognized ALS researcher, as PI. Goldstein inherited the PI role. It's not his grant, it's the team's grant.
ReplyDeleteGood distinction! Important because there is no "my" in TEAM!
ReplyDelete